A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 15 Jun 2017
At a glance
- Drugs AT 406 (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Debiopharm
- 15 Jun 2017 Top-line results from this trial are expected in Q1 2019 according to a Debiopharm International media release.
- 10 Jun 2017 Biomarkers information updated
- 18 May 2017 Planned End Date changed from 1 Jun 2019 to 1 Apr 2019.